- Home
- NSPR vs RAPT Comparison
NSPR vs RAPT Comparison
Compare NSPR & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSPR
- RAPT
- Stock Information
- Founded
- NSPR 2005
- RAPT 2015
- Country
- NSPR Israel
- RAPT United States
- Employees
- NSPR N/A
- RAPT N/A
- Industry
- NSPR Medical/Dental Instruments
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- NSPR Health Care
- RAPT Health Care
- Exchange
- NSPR Nasdaq
- RAPT Nasdaq
- Market Cap
- NSPR 63.0M
- RAPT 65.6M
- IPO Year
- NSPR N/A
- RAPT 2019
- Fundamental
- Price
- NSPR $2.45
- RAPT $1.52
- Analyst Decision
- NSPR Buy
- RAPT Hold
- Analyst Count
- NSPR 1
- RAPT 10
- Target Price
- NSPR $4.50
- RAPT $5.00
- AVG Volume (30 Days)
- NSPR 36.4K
- RAPT 920.1K
- Earning Date
- NSPR 11-12-2024
- RAPT 11-12-2024
- Dividend Yield
- NSPR N/A
- RAPT N/A
- EPS Growth
- NSPR N/A
- RAPT N/A
- EPS
- NSPR N/A
- RAPT N/A
- Revenue
- NSPR $6,821,000.00
- RAPT N/A
- Revenue This Year
- NSPR $12.28
- RAPT N/A
- Revenue Next Year
- NSPR $53.44
- RAPT N/A
- P/E Ratio
- NSPR N/A
- RAPT N/A
- Revenue Growth
- NSPR 24.70
- RAPT N/A
- 52 Week Low
- NSPR $1.81
- RAPT $1.25
- 52 Week High
- NSPR $3.42
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- NSPR 61.14
- RAPT 39.12
- Support Level
- NSPR $2.07
- RAPT $1.31
- Resistance Level
- NSPR $3.05
- RAPT $1.96
- Average True Range (ATR)
- NSPR 0.22
- RAPT 0.37
- MACD
- NSPR 0.03
- RAPT -0.09
- Stochastic Oscillator
- NSPR 63.92
- RAPT 10.67
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.